News

LIPO-102 is Lithera’s novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction. LIPO-102 is currently under development for the treatment of

As per the agreement, Synosia will be responsible for SYN-115 and SYN-118 through Phase II clinical development. UCB will be responsible for Phase III clinical development and commercialisation.

The patent application was among the assets Columbia Laboratories sold to Watson in July 2010. The patent will cover Crinone and Prochieve (progesterone gels) and any products in

As per the new seven year supply agreement, Caliper Life Sciences is expected to continue to be the exclusive supplier of the microfluidic chips used in Agilent’s Bioanalyzer

The objective of the Folotyn Phase 2b study (PDX-012) was to estimate the efficacy of Folotyn relative to that of erlotinib as assessed by OS, the primary endpoint

Lathbury is expected to report to Steven Hagen, vice president of Pharmaceutical Development and Manufacturing. Lathbury will assume leadership for AMRI’s Chemical Development business including operations in Albany,

Thallion Pharma has posted a net loss of $351,394 for the third quarter 2010, or $0.01 loss per diluted share, compared to net loss of $3.03m, or $0.09

Vivalis claimed that the EB66 cell line, derived from avian embryonic stem cells, presents characteristics such as genetic stability, immortality and cell growth up to high cell densities

Alkermes claimed that Vivitrol is a non-narcotic, non-addictive, once-monthly medication approved for the treatment of opioid dependence. The FDA approval of Vivitrol for the prevention of relapse to